News

New Study Demonstrates Significantly Increased Healing Rates with NATROX® O₂

Inotec AMD, manufacturer of NATROX® Oxygen Wound Therapy, is delighted to share newly published randomised controlled trial (RCT) results. The trial involved 145 patients with previously non-healing diabetic foot ulcers (DFUs) and compared the effects of using standard care against a combination of standard care plus NATROX® Oxygen Wound Therapy. Patients completing the therapy experienced 71% greater healing rates and 73% greater reduction in wound size using NATROX®. These results offer hope to patients suffering from chronic wounds.

Read More
NATROX® US Randomized Control Trial (RCT) submitted for publication

March 09, 2021
Jane Clark, VP Global Marketing & Clinical Affairs, in Top 25 Women Leaders in Medical Devices 2021

January 28, 2021
NATROX® O₂ Wins the “Best Wearable Tech in Health Care” Award

December 08, 2020
Inotec AMD Expands Global Headquarter Office in Cambridge, UK

November 16, 2020
Craig Kennedy, Inotec AMD, included in the 10 Best Inspiring CEOs of 2020

October 06, 2020
NATROX® O₂ Featured at International Scientific Conference

September 14, 2020
Dr. Harikrishna KR Nair initiates a NATROX® O₂ Clinical Trial in Malaysia

June 24, 2020
National Institute for Health and Care Excellence (NICE) briefing on NATROX®

April 07, 2020
Inotec Receives Federal Supply Schedule (FSS) award

March 02, 2020